Letters to the Editor
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases

Psychiatric Symptoms after H1N1 Influenza Treated with Baloxavir Marboxil in Two Patients with Hematologic Malignancies

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: February 28, 2026
483
Views
240
Downloads
58
HTML

Authors

A subset of patients with influenza A (H1N1) infection developed psychiatric symptoms during the course of illness, the etiology of which is likely multifactorial. 

Downloads

Download data is not yet available.

Citations

[1] Trzepacz, P. T.; Mittal, D.; Torres, R.; Kanary, K.; Norton, J.; Jimerson, N. Validation of the Delirium Rating Scale-Revised-98: Comparison with the Delirium Rating Scale and the Cognitive Test for Delirium. J Neuropsychiatry Clin Neurosci, 2001, 13 (2), 229–242. https://doi.org/10.1176/jnp.13.2.229.
[2] Grover, S. Assessment Scales for Delirium: A Review. World J Psychiatr, 2012, 2 (4), 58. https://doi.org/10.5498/wjp.v2.i4.58.
[3] Mizuguchi, M. Influenza Encephalopathy and Related Neuropsychiatric Syndromes. Influenza Resp Viruses, 2013, 7 (s3), 67–71. https://doi.org/10.1111/irv.12177.
[4] Hayden, F. G.; Sugaya, N.; Hirotsu, N.; Lee, N.; De Jong, M. D.; Hurt, A. C.; Ishida, T.; Sekino, H.; Yamada, K.; Portsmouth, S.; et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med, 2018, 379 (10), 913–923. https://doi.org/10.1056/NEJMoa1716197.
[5] Zhou, J.; Ye, J.; Chen, M.; Zheng, X. A Real-World Disproportionality Analysis of Baloxavir Marboxil: Post-Marketing Pharmacovigilance Data. Expert Opinion on Drug Safety, 2024, 1–9. https://doi.org/10.1080/14740338.2024.2393269.
[6] Zhou, Y.; Jin, L.; Lai, X.; Li, Y.; Sheng, L.; Xie, G.; Fang, J. Adverse Events Associated with Oseltamivir and Baloxavir Marboxil in against Influenza Virus Therapy: A Pharmacovigilance Study Using the FAERS Database. PLoS ONE, 2024, 19 (11), e0308998. https://doi.org/10.1371/journal.pone.0308998.
[7] Li, Y.; Wang, X.; Liao, Y.; Zeng, Y.; Lin, W.; Zhuang, W. Safety Analysis of Oseltamivir and Baloxavir Marboxil after Market Approval: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System. Bmc Infect Dis, 2024, 24 (1), 446. https://doi.org/10.1186/s12879-024-09339-4.
[8] Naranjo, C. A.; Busto, U.; Sellers, E. M.; Sandor, P.; Ruiz, I.; Roberts, E. A.; Janecek, E.; Domecq, C.; Greenblatt, D. J. A Method for Estimating the Probability of Adverse Drug Reactions. Clin Pharmacol Ther, 1981, 30 (2), 239–245. https://doi.org/10.1038/clpt.1981.154.
[9] Pasyk, S.; Maharaj, S.; Bourgeois, J. A. Psychotoxicity of Immunomodulators: Corticosteroids, Mycophenolate, Tacrolimus, Cyclophosphamide, and Hydroxychloroquine. In Psychonephrology; Hategan, A., Bourgeois, J. A., Gangji, A. S., Woo, T. K. W., Eds.; Springer International Publishing: Cham, 2022; pp 241–252. https://doi.org/10.1007/978-3-030-84740-1_14.
[10] Brouns, R.; De Deyn, P. P. Neurological Complications in Renal Failure: A Review. Clin Neurol Neurosur, 2004, 107 (1), 1–16. https://doi.org/10.1016/j.clineuro.2004.07.012.
[11] Grill, M. F.; Maganti, R. K. Neurotoxic Effects Associated with Antibiotic Use: Management Considerations. Brit J Clin Pharmaco, 2011, 72 (3), 381–393. https://doi.org/10.1111/j.1365-2125.2011.03991.x.

Ethics Approval

Psychogenia, influenza infection, Baloxavir marboxil, hematological malignancy

How to Cite



“Psychiatric Symptoms after H1N1 Influenza Treated with Baloxavir Marboxil in Two Patients with Hematologic Malignancies” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1). doi:10.4084/MJHID.2026.031.